This mirrors findings in leukemic B-cells from patients with chronic lymphocytic leukemia (CLL), where the surviving B cells show higher BCL-2 expression following venetoclax treatment42,43. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.